Trait: insulin secretion measurement

Experimental Factor Ontology (EFO) Information
Identifier EFO_0008001
Description Measurement of compounds, generally C-peptide or mature insulin, whose levels quantify insulin secretion from the pancreas.
Trait category
Other measurement
Synonym insulin secretion rate measurement
Mapped term http://orcid.org/0000-0001-9043-693X

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported
Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution
GWAS
Dev
Eval
 Scoring File (FTP Link)
PGS000835
(ISR)
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Insulin secretion rate insulin secretion measurement 319
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000835/ScoringFiles/PGS000835.txt.gz
PGS000871
(IS_14)
 PGP000214 |
Aksit MA et al. J Clin Endocrinol Metab (2020)
 Insulin secretion insulin secretion measurement 14
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000871/ScoringFiles/PGS000871.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		Evaluated Score PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM002258 PGS000835
(ISR)
 PSS001086|
European Ancestry|
3,194 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Autoimmune Diabetes OR: 1.06 [0.96, 1.17] — — PC1-10 —
PPM002259 PGS000835
(ISR)
 PSS001087|
European Ancestry|
3,930 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Deficient Diabetes OR: 0.84 [0.78, 0.9] — — PC1-10 —
PPM002260 PGS000835
(ISR)
 PSS001088|
European Ancestry|
3,869 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Severe Insulin-Resistant Diabetes OR: 1.02 [0.95, 1.1] — — PC1-10 —
PPM002261 PGS000835
(ISR)
 PSS001085|
European Ancestry|
4,116 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Obesity-related Diabetes OR: 0.89 [0.83, 0.95] — — PC1-10 —
PPM002262 PGS000835
(ISR)
 PSS001084|
European Ancestry|
5,597 individuals
 PGP000211 |
Aly DM et al. Nat Genet (2021)
 Reported Trait: Moderate Age-Related Diabetes OR: 0.88 [0.83, 0.92] — — PC1-10 —
PPM020178 PGS000835
(ISR)
 PSS011301|
South Asian Ancestry|
1,282 individuals
 PGP000525 |
Yajnik CS et al. Lancet Reg Health Southeast Asia (2023)
|Ext.		 Reported Trait: Type 2 diabetes OR: 0.72 [0.6, 0.85] — — age, sex and BMI —
PPM020191 PGS000835
(ISR)
 PSS011302|
South Asian Ancestry|
830 individuals
 PGP000525 |
Yajnik CS et al. Lancet Reg Health Southeast Asia (2023)
|Ext.		 Reported Trait: Severe insulin deficiency diabetes OR: 0.86 [0.74, 0.99] — — sex —
PPM002416 PGS000871
(IS_14)
 PSS001092|
Ancestry Not Reported|
5,740 individuals
 PGP000214 |
Aksit MA et al. J Clin Endocrinol Metab (2020)
 Reported Trait: Cystic-fibrosis related diabetes onset HR: 1.247 — — PCs(1-4), site of recruitment —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS001092 All individuals had cystic fibrosis with either 2 severe CFTR mutations and/or clinically diagnosed exocrine pancreatic insufficiency. Cases are individuals with cystic fibrosis related diabetes (CFRD).Phenotypes were obtained from extracted medical charts and CF Foundation Patient Registry through 2011. CFRD was defined by clinician diagnosis of diabetes plus insulin treatment for at least 1 year. The onset of CFRD was defined as the date at which insulin was started, if it was subsequently continued for at least 1 year. In approximately 50% of the participants, independent laboratory data (such as oral glucose tolerance test or hemoglobin A1c) were able to independently confirm the diagnosis of CFRD. Diabetes data were censored at the last clinic visit or date of solid organ transplant. —
[
  • 1,341 cases
  • , 4,399 controls
]
,
47.04 % Male samples
 Mean = 20.0 years Not reported — CGS, CWRU, FrGMC, JHU, UNC —
PSS011301 — —
[
  • 821 cases
  • , 461 controls
]
 — South Asian
(Indian)		 — WellGen —
PSS011302 — —
[
  • 369 cases
  • , 461 controls
]
 — South Asian
(Indian)		 — WellGen —
PSS001084 Moderate Age-Related Diabetes (MARD) vs. controls —
[
  • 2,853 cases
  • , 2,744 controls
]
 — European Swedish ANDIS —
PSS001085 Moderate Obesity-related Diabetes (MOD) vs. controls —
[
  • 1,372 cases
  • , 2,744 controls
]
 — European Swedish ANDIS —
PSS001086 Severe Autoimmune Diabetes (SAID) vs. controls —
[
  • 450 cases
  • , 2,744 controls
]
 — European Swedish ANDIS —
PSS001087 Severe Insulin-Deficient Diabetes (SIDD) vs. controls —
[
  • 1,186 cases
  • , 2,744 controls
]
 — European Swedish ANDIS —
PSS001088 Severe Insulin-Resistant Diabetes (SIRD) vs. controls —
[
  • 1,125 cases
  • , 2,744 controls
]
 — European Swedish ANDIS —